Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial 14 May 2024 (08:54 - 09:02) Organised by: Slides About the speaker University College London, London (United Kingdom of Great Britain & Northern Ireland) 9 More presentations in this session Professor F
[1] A common starting regimen in adults with normal renal and hepatic function is 1 mL intramuscularly once or twice weekly, titrated every four weeks according to biochemical markers such as fasting lipid panel, liver transaminases, and serum carnitine
2024;14(3):e3448
Saleem S, Kazmi I, Ahmad A, Abuzinadah MF, Samkari A, Alkrathy HM, Khan R (2020) Thiamin regresses the anticancer efficacy of methotrexate in the amelioration of diethyl nitrosamine-induced hepatocellular carcinoma in Wistar strain rats
Key Takeaways Tirzepatide does not directly increase testosterone, but weight loss from the medication may support healthier hormonal function
Secondary outcomes included endoscopy use and prescriptions for gastrointestinal medications such as laxatives and prokinetics